静脉依特卡肽治疗血液透析患者继发性甲状旁腺功能亢进的一年安全性与有效性
该开放标签扩展研究纳入来自三项母试验的血液透析继发性甲状旁腺功能亢进患者,评估静脉依特卡肽治疗52周的安全性与有效性。结果显示89.8%患者发生至少一次治疗中出现的不良事件,最常见为血钙降低(43.3%),约68%患者PTH降低>30%,PTH持续下降且无新安全性信号。
要点
- 依特卡肽可有效降低PTH,约68%患者PTH降低>30%,约56%达到PTH≤300 pg/mL。
- 最常见不良事件为血钙降低(43.3%),症状性低钙血症发生率为3.7%。
- 52周治疗期间PTH、钙、磷及钙磷乘积均持续下降,无新安全性问题。
核心结论
- 依特卡肽有效降低PTH且效果持续,一年治疗期间未出现新的安全性问题。
研究设计与样本
- 52周、多中心、单臂开放标签扩展试验,纳入来自三项母试验的血液透析继发性甲状旁腺功能亢进患者。
主要发现
- 89.8%患者发生至少一次治疗中出现的不良事件,最常见为血钙降低(43.3%)、腹泻(10.8%)、呕吐(10.4%)和恶心(9.6%)。
- 症状性低钙血症发生于3.7%的患者。
- 约68%患者PTH较基线降低>30%,约56%患者达到PTH≤300 pg/mL。
- PTH平均较基线变化范围为-25.4%至-26.1%,钙为-8.3%至-9.1%,磷为-3.6%至-4.1%,钙磷乘积为-12.0%至-12.6%。
临床怎么用
- 依特卡肽可用于血液透析继发性甲状旁腺功能亢进患者的长期治疗,需监测血钙及低钙血症相关症状。
局限性
- 为单臂开放标签扩展研究,无对照组,安全性结论需结合母试验随机对照数据解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary hyperparathyroidism (sHPT), a common complication of chronic kidney disease, is characterized by elevated serum parathyroid hormone (PTH). Etelcalcetide is an intravenous calcimimetic that increases sensitivity of the calcium-sensing receptor to calcium and decreases PTH secretion. This open-label extension (OLE) trial evaluated the long-term effects of etelcalcetide for sHPT treatment in patients receiving hemodialysis. METHODS: This 52-week, multicenter, single-arm OLE enrolled patients from three parent trials: two randomized, double-blind, placebo-controlled trials and one open-label, single-arm, 'switch' study from cinacalcet to etelcalcetide. The primary endpoint was to investigate the nature, frequency, severity and relation to treatment of all adverse events (AEs) reported throughout the trial. Secondary endpoints included the proportion of patients with >30% reduction from baseline in PTH and the percentage change from baseline in PTH, albumin-corrected calcium (Ca), phosphate (P) and the calcium-phosphate product (Ca × P).ClinicalTrials.gov identifier: NCT01785875; Amgen study: 20120231. RESULTS: Overall, 89.8% of the patients experienced one or more treatment-emergent AE. The most common were decreased blood Ca (43.3%), diarrhea (10.8%), vomiting (10.4%) and nausea (9.6%); symptomatic hypocalcemia occurred in 3.7% of the patients. Approximately 68% of patients achieved >30% reduction in PTH, and ∼56% achieved PTH ≤300 pg/mL. Mean percent changes from baseline ranged from -25.4% to -26.1% for PTH, -8.3% to -9.1% for Ca, -3.6% to -4.1% for P and -12.0% to -12.6% for Ca × P. CONCLUSIONS: Etelcalcetide effectively lowered PTH and its effect was sustained, while no new safety concerns emerged over a 1-year treatment period.
引用
- Bushinsky DA, Chertow GM, Cheng S, et al. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant. 2020. PMID: 30859218. doi:10.1093/ndt/gfz039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。